BRPI0922650A2 - Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina - Google Patents
Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodinaInfo
- Publication number
- BRPI0922650A2 BRPI0922650A2 BRPI0922650A BRPI0922650A BRPI0922650A2 BR PI0922650 A2 BRPI0922650 A2 BR PI0922650A2 BR PI0922650 A BRPI0922650 A BR PI0922650A BR PI0922650 A BRPI0922650 A BR PI0922650A BR PI0922650 A2 BRPI0922650 A2 BR PI0922650A2
- Authority
- BR
- Brazil
- Prior art keywords
- compound
- compounds
- diabetic nephropathy
- sinaptopodin
- pharmaceutical composition
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 9
- 238000000034 method Methods 0.000 title abstract 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 title abstract 3
- 208000033679 diabetic kidney disease Diseases 0.000 title abstract 3
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 102000014156 AMP-Activated Protein Kinases Human genes 0.000 abstract 2
- 108010011376 AMP-Activated Protein Kinases Proteins 0.000 abstract 2
- 239000003642 reactive oxygen metabolite Substances 0.000 abstract 2
- 102100035604 Synaptopodin Human genes 0.000 abstract 1
- 101710119889 Synaptopodin Proteins 0.000 abstract 1
- 239000000090 biomarker Substances 0.000 abstract 1
- 230000000694 effects Effects 0.000 abstract 1
- 230000014101 glucose homeostasis Effects 0.000 abstract 1
- 238000000338 in vitro Methods 0.000 abstract 1
- 238000012544 monitoring process Methods 0.000 abstract 1
- 230000001575 pathological effect Effects 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 238000012216 screening Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
- C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
- C07D251/10—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Biomedical Technology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Pain & Pain Management (AREA)
- Cardiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Ophthalmology & Optometry (AREA)
- Child & Adolescent Psychology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Urology & Nephrology (AREA)
- Emergency Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
COMPOSTO, COMPOSIÇÃO FARMACÊUTICA, USO DE PELO MENOS UM COMPOSTO, MÉTODOS PARA TRATAR DOENÇAS, PARA DIAGNOSTICAR NEFROPATIA DIABÉTICA, E PARA TRIAR COMPOSTOS, E, USO DE SINAPTOPODINA. A invenção refere-se a compostos da fórmula (1) em que os radicais R1 a R6 têm o significado de acordo com a reivindicação 1, e/ou sais fisiologicamente aceitáveis do mesmos, para o tratamento profilático ou terapêutico e/ou monitoramento de condições fisiológicas e/ou patológicas que são associadas com a atividade de proteína cinase ativada por AMP (AMPK). Um outro objetivo da invenção diz respeito ao uso dos ditos compostos para realçar a homeostase da glicose, melhorar a podocitopatia e/ou diminuir a produção de espécies de oxigênio reativo (ROS). A invenção também refere-se a um método para diagnosticar nefropatia diabética in vitro e um método para triar compostos que reduzem a podocitopatia, em cada caso aplicando-se sinaptopodina como biomarcador.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP08021618 | 2008-12-12 | ||
| PCT/EP2009/066999 WO2010066901A2 (en) | 2008-12-12 | 2009-12-11 | Tetrahydrotriazine compounds for treating diseases associated with ampk activity |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BRPI0922650A2 true BRPI0922650A2 (pt) | 2017-07-11 |
Family
ID=42026760
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BRPI0922650A BRPI0922650A2 (pt) | 2008-12-12 | 2009-12-11 | Composto, composição farmacêutica, uso de pelo menos um composto, métodos para tratar doenças, para diagnosticar nefropatia diabética, e para triar compostos, e, uso de sinaptopodina |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9035048B2 (pt) |
| EP (1) | EP2367802B1 (pt) |
| JP (1) | JP5485292B2 (pt) |
| CN (1) | CN102245581A (pt) |
| AU (1) | AU2009326965A1 (pt) |
| BR (1) | BRPI0922650A2 (pt) |
| CA (1) | CA2745854A1 (pt) |
| ES (1) | ES2573266T3 (pt) |
| IL (1) | IL212901A0 (pt) |
| MX (1) | MX2011005644A (pt) |
| TW (1) | TW201033182A (pt) |
| WO (1) | WO2010066901A2 (pt) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20110565A1 (es) | 2008-08-12 | 2011-09-02 | Zinfandel Pharmaceuticals Inc | Metodo de identificacion de factores de riesgo de la enfermedad |
| US8846315B2 (en) | 2008-08-12 | 2014-09-30 | Zinfandel Pharmaceuticals, Inc. | Disease risk factors and methods of use |
| FR2948026B1 (fr) * | 2009-07-17 | 2011-12-02 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine |
| FR2948027A1 (fr) * | 2009-07-17 | 2011-01-21 | Merck Sante Sas | Derives amines de dihydro-1,3,5-triazine pour leur utilisation dans le traitement des maladies associees a une ischemie et/ou une reperfusion |
| ES2577930T3 (es) * | 2010-06-09 | 2016-07-19 | Poxel | Derivados de triazina para retrasar el inicio de la diabetes tipo 1 |
| US11974971B2 (en) | 2011-01-07 | 2024-05-07 | Anji Pharmaceuticals Inc. | Compositions and methods for treating metabolic disorders |
| US9211263B2 (en) | 2012-01-06 | 2015-12-15 | Elcelyx Therapeutics, Inc. | Compositions and methods of treating metabolic disorders |
| PT2661266T (pt) | 2011-01-07 | 2020-11-30 | Anji Pharma Us Llc | Terapias com base em ligandos do recetor quimiossensorial |
| US11759441B2 (en) | 2011-01-07 | 2023-09-19 | Anji Pharmaceuticals Inc. | Biguanide compositions and methods of treating metabolic disorders |
| EA201391017A1 (ru) | 2011-01-10 | 2014-04-30 | Зинфандел Фармасьютикалз, Инк. | Способы и готовые лекарственные формы для лечения болезни альцгеймера |
| MX2014008190A (es) | 2012-01-06 | 2015-02-04 | Elcelyx Therapeutics Inc | Composiciones de biguanida y métodos para tratar transtornos metabólicos. |
| SG10201901922VA (en) * | 2012-01-06 | 2019-04-29 | Elcelyx Therapeutics Inc | Compositions and methods for treating metabolic disorders |
| WO2015002818A1 (en) * | 2013-07-01 | 2015-01-08 | Emory University | Treating or preventing nephrogenic diabetes insipidus |
| JP7051109B2 (ja) * | 2016-10-31 | 2022-04-11 | 国立大学法人京都大学 | がん細胞にプログラム細胞死を誘導するための医薬組成物 |
| FR3068601B1 (fr) * | 2017-07-05 | 2021-02-19 | Eric Joseph Marie Fulgence Janin | Utilisation de l'imeglimine pour la prevention et/ou le traitement du carcinome hepatocellulaire |
| US11617754B2 (en) | 2017-10-02 | 2023-04-04 | Poxel Sa | Methods of treating heart failure with preserved ejection fraction |
| MX2020013210A (es) * | 2018-06-06 | 2021-02-26 | Metavant Sciences Gmbh | Metodos de tratamiento de sujetos que padecen diabetes con enfermedad renal cronica. |
| EP3806828A1 (en) | 2018-06-14 | 2021-04-21 | Poxel | Film-coated tablet comprising a triazine derivative for use in the treatment of diabetes |
| CN116323608A (zh) | 2020-05-19 | 2023-06-23 | 卡尔优普公司 | Ampk活化剂 |
| EP4172162A4 (en) | 2020-06-26 | 2024-08-07 | Kallyope, Inc. | AMPK ACTIVATORS |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3629467A (en) * | 1969-10-17 | 1971-12-21 | Armour Pharma | Pharmaceutical preparations containing a 2 4-diamino-6-substituted-s-triazine and methods of using same |
| WO1991001733A1 (fr) * | 1989-08-09 | 1991-02-21 | Nippon Shinyaku Co., Ltd. | Remede |
| FR2804113B1 (fr) * | 2000-01-26 | 2004-06-18 | Lipha | Derives animes de dihydro-1,3,5-triazine et leurs applications en therapeutique |
| GB2397301A (en) * | 2003-01-14 | 2004-07-21 | Novo Pharmaceuticals Ltd De | Substituted 1,3,5-triazine derivatives |
| WO2005030735A1 (en) * | 2003-09-25 | 2005-04-07 | Ranbaxy Laboratories Limited | Triazines derivatives as cell adhesion inhibitors |
| FR2896158B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'inhibiteurs de la hmg-coa reductase. |
| FR2896159B1 (fr) * | 2006-01-13 | 2008-09-12 | Merck Sante Soc Par Actions Si | Combinaison de derives de triazine et d'agents sensibilisateurs a l'insuline. |
-
2009
- 2009-12-11 CN CN2009801499067A patent/CN102245581A/zh active Pending
- 2009-12-11 WO PCT/EP2009/066999 patent/WO2010066901A2/en not_active Ceased
- 2009-12-11 TW TW098142584A patent/TW201033182A/zh unknown
- 2009-12-11 AU AU2009326965A patent/AU2009326965A1/en not_active Abandoned
- 2009-12-11 BR BRPI0922650A patent/BRPI0922650A2/pt not_active IP Right Cessation
- 2009-12-11 ES ES09799313.3T patent/ES2573266T3/es active Active
- 2009-12-11 JP JP2011540126A patent/JP5485292B2/ja active Active
- 2009-12-11 EP EP09799313.3A patent/EP2367802B1/en active Active
- 2009-12-11 US US12/998,848 patent/US9035048B2/en active Active
- 2009-12-11 CA CA2745854A patent/CA2745854A1/en not_active Abandoned
- 2009-12-11 MX MX2011005644A patent/MX2011005644A/es not_active Application Discontinuation
-
2011
- 2011-05-16 IL IL212901A patent/IL212901A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| CA2745854A1 (en) | 2010-06-17 |
| EP2367802A2 (en) | 2011-09-28 |
| WO2010066901A2 (en) | 2010-06-17 |
| US20110236317A1 (en) | 2011-09-29 |
| AU2009326965A1 (en) | 2011-06-23 |
| WO2010066901A3 (en) | 2010-08-05 |
| TW201033182A (en) | 2010-09-16 |
| IL212901A0 (en) | 2011-07-31 |
| JP2012511549A (ja) | 2012-05-24 |
| EP2367802B1 (en) | 2016-04-20 |
| ES2573266T3 (es) | 2016-06-06 |
| MX2011005644A (es) | 2011-06-16 |
| JP5485292B2 (ja) | 2014-05-07 |
| US9035048B2 (en) | 2015-05-19 |
| CN102245581A (zh) | 2011-11-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2010066901A3 (en) | Tetrahydrotriazine compounds for treating diseases associated with ampk activity | |
| ECSP099414A (es) | Derivados de dihidropiridina de utilidad como inhibidores de la proteína quinasa | |
| BRPI0507442B8 (pt) | método in vitro de diagnóstico de um indivíduo humano gestante como apresentando ou com uma propensão a desenvolver pré-eclâmpsia ou eclâmpsia | |
| EP2344475A4 (en) | QUINAZOLINONE, QUINOLONE AND RELATED ANALOGUES AS MODULATORS OF SIRTUINE | |
| EA201070035A1 (ru) | Модулирующие сиртуин соединения | |
| EA201070034A1 (ru) | Модулирующие сиртуин производные имидазотиазола | |
| BRPI0822162A8 (pt) | método para tratamento de doenças das unhas ou leito ungueal e composição farmacêutica para tratamento tópico de doença das unhas ou leito ungueal. | |
| MX2009012307A (es) | Tratamiento de sinucleinopatias. | |
| BR112013010015A2 (pt) | aparelho e método para detecção não invasiva de doenças que afetam as propriedades estruturais em tecidos biológicos | |
| WO2009134973A8 (en) | Quinolines and related analogs as sirtuin modulators | |
| BRPI0717697A2 (pt) | composto, composição farmaceutica, uso do composto, método para tratar um paciente sofrendo de uma condição patológica ou uma doença e combinação de produtos | |
| EA200901583A1 (ru) | N-(2-(гетарил)арил)арилсульфонамиды и n-(2-(гетарил)гетарил)арилсульфонамиды | |
| BRPI0908026B8 (pt) | uso de rifaximina no tratamento de doenças do intestino | |
| EA201290078A1 (ru) | Гетероциклические соединения для ингибирования pask | |
| NO20080408L (no) | Azaindazolforbindelser og anvendelse derav | |
| EA201300522A1 (ru) | Фармацевтические комбинации для лечения метаболических нарушений | |
| DOP2011000045A (es) | Anticuerpos monoclonales contra el inhibidor de la via del factor tisular (tfpi) | |
| BR112013021125A2 (pt) | método para regular os níveis de glicose no sangue, método para aumentar a secreção da insulina ou promover a liberação da insulina na corrente sanguínea, método para tratar uma doença ou condição, método para retardar o ínicio de uma doença ou condição de doença kit, composto de composição farmacêutica | |
| EA200901550A1 (ru) | Способы лечения, диагностирования и выявления ассоциированных с fgf21 нарушений | |
| BR112014031414A2 (pt) | métodos de detectar doenças ou condições utilizando células doentes circulantes | |
| MX2011006475A (es) | Ftalazinona y analogos relacionados como moduladores de sirtuina. | |
| BR112014014960A2 (pt) | métodos para o diagnóstico da doença de alzheimer | |
| EA201200975A1 (ru) | Тиено[2,3-b]пиридиндионовые активаторы амфк и их терапевтическое применение | |
| MX2010005186A (es) | Tiazolopiridinas solubilizadas. | |
| EA201270316A1 (ru) | Галектин-3 и сердечная ресинхронизирующая терапия |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] | ||
| B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |